Overactivation of PI3K/AKT/mTOR has been proposed as a mechanism for resistance of HCC to sorafenib, and mTOR inhibitor causing feedback activation of AKT has been reported in some cases [12]. The gene discussed is AKT1; the disease is hepatocellular carcinoma.